Cover Image

Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer

<b>Background</b>: Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths globally. The most extensive treatment is Tyrosine Kinase Inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) overexpression. Osimertinib, a third-generation TKI is approved to tar...

Full description

Saved in:

Bibliographic Details
Main Authors:	Apoorva Daram (Author), Shruti S. Sawant (Author), Dhwani A. Mehta (Author), Carlos A. Sanhueza (Author), Nitesh K. Kunda (Author)
Format:	Book
Published:	MDPI AG, 2024-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation-Positive Lung Cancer Cells
by: Paulina Skupin-Mrugalska, et al.
Published: (2020)

Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment
by: Vineela Parvathaneni, et al.
Published: (2020)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Gengwei Huo, et al.
Published: (2024)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
by: Yue Zeng, et al.
Published: (2022)

Targeting EGFR and Monitoring Tumorigenesis of Human Lung Cancer Cells In Vitro and In Vivo Using Nanodiamond-Conjugated Specific EGFR Antibody
by: Yu-Wei Lin, et al.
Published: (2022)

Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report
by: Jowan Al-Nusair MD, et al.
Published: (2024)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018)

Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
by: Jingjing Shi, et al.
Published: (2023)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
by: Caterina Gianni, et al.
Published: (2021)

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review
by: Xiaofei Gu, et al.
Published: (2024)

Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
by: Thomas Rodier, et al.
Published: (2022)

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
by: Yan Hu, et al.
Published: (2022)

Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles
by: Linlin Yang, et al.
Published: (2023)

Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers
by: Tongtong Zhang, et al.
Published: (2018)

Intestinal Haemorrhage and Colitis Induced by Treatment With Osimertinib for Non-Small-Cell Lung Carcinoma: A Case Report
by: Wang Shujun, et al.
Published: (2022)

Design of Experiment (DoE) Approach for Developing Inhalable PLGA Microparticles Loaded with Clofazimine for Tuberculosis Treatment
by: Druva Sarika Rongala, et al.
Published: (2024)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
by: Gang Shen, et al.
Published: (2021)

Subacute cutaneous lupus erythematosus following osimertinib therapy for non-small cell lung cancer: A case report
by: Eun Jae Kim, BA, et al.
Published: (2024)

Combined Role of Interleukin-15 Stimulated Natural Killer Cell-Derived Extracellular Vesicles and Carboplatin in Osimertinib-Resistant H1975 Lung Cancer Cells with EGFR Mutations
by: Aakash Nathani, et al.
Published: (2024)

Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates
by: Anjong Florence Tikum, et al.
Published: (2022)

Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer
by: Karthick Vishwanathan, et al.
Published: (2020)

Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep
by: Jibriil P Ibrahim, et al.
Published: (2022)

Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer
by: Yongkuan Guo, et al.
Published: (2024)

miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44
by: Shang-Gin Wu, et al.
Published: (2024)

EGFR-gene analysis on cytological specimens of non-small-cell lung cancers
by: Feichter G, et al.
Published: (2007)

Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial
by: Jialin Yao, et al.
Published: (2022)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy
by: Wiebke Sihver, et al.
Published: (2014)

Osimertinib-associated ashy dermatosis-like hyperpigmentation
by: Pattamon Lertpichitkul, MD, et al.
Published: (2020)

Identification of super-enhancer-driven peptidyl arginine deiminases as potential biomarkers and therapeutic targets for osimertinib-resistant non-small cell lung cancer
by: Hang Li, et al.
Published: (2022)

CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients
by: Teerapat Majam, et al.
Published: (2023)

EGFR mutation testing in non-small cell lung cancer (NSCLC)
by: Fouad Al Dayel
Published: (2012)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

Discovery of potent allosteric antibodies inhibiting EGFR
by: Léxane Fournier, et al.
Published: (2024)

In Vitro Characterization of Inhalable Cationic Hybrid Nanoparticles as Potential Vaccine Carriers
by: Iman M. Alfagih, et al.
Published: (2021)

Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer: Case Report
by: Haifeng Qin, et al.
Published: (2021)

Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET
by: Hiroki Matsumoto, et al.
Published: (2022)

Systemic Protein Delivery via Inhalable Liposomes: Formulation and Pharmacokinetics
by: Pranav Ponkshe, et al.
Published: (2023)

Clinical and surgical implications of EGFR mutations in non-small cell lung cancer
by: M. Yoon, et al.
Published: (2016)